Lv1
60 积分 2026-07-28 加入
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
3小时前
已关闭
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL
3小时前
已关闭
Building the future management of follicular lymphoma with T-cell–redirecting strategies
7天前
已完结
Classic Hodgkin Lymphoma
1个月前
已完结
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study
1个月前
已完结
CAR T-cell therapy for patients with relapsed or refractory marginal zone lymphoma
1个月前
已完结
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study
2个月前
已完结
皖公网安备34019202002308
